Cancer Related Funding Opportunities

Defense Health Program Department of Defense Breast Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)

The Fiscal Year 2021 (FY21) Defense Appropriations Bill has not been signed into law. Although FY21 funds have not been appropriated for the Department of Defense Breast Cancer Research Program (BCRP), the BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.

The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

Subject to the FY21 Congressional appropriation for BCRP funding, FY21 BCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.

Applications submitted to the FY21 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

More Information

March 2021 Application Deadlines

03/08/2021 - Neuroendocrine Tumor Research Foundation: Neuroendocrine Cancer Research Grants

Deadline: March 8, 2021

Amount/Duration: Accelerator: $1.2M, Investigator: $300K, Pilot: $100K, Mentored: $120K

Eligibility: See website for requirements for each award.

About: The Foundation invites innovative and transformative research proposals in NETs to help bring the field closer to more effective therapies. We are equally interested in basic, translational, and clinical research applications, and encourage collaborations between investigators with expertise in different fields. Some areas of interest include but not limited to:

  • Application of existing or new technologies to target NETs
  • New/optimized experimental models
  • Cancer metabolism
  • Deciphering the molecular underpinnings of NETs
  • Diagnostics
  • Clinical Research
  • Cell invasion and metastasis
  • Immune microenvironment
  • Nuclear medicine, theranostics, imaging

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

June 2021 Application Deadlines

06/15/2021 - New York State Department of Health/Health Research, Inc. Comprehensive Cancer Control Program

Health Research, Inc. (HRI) and the New York State Department of Health (NYSDOH) Comprehensive Cancer Control Program are soliciting applications from organizations to conduct projects in support of the New York State Comprehensive Cancer Control Plan and the work of the New York State Cancer Consortium (Consortium) action teams. The Consortium is a voluntary network of individuals and organizations that collaborate to address New York’s cancer burden. The Consortium recommends statewide and local interventions to: prevent skin cancer, promote the human papillomavirus (HPV) vaccine, promote programs and services to increase quality of life for cancer survivors, and prevent and promote early detection of colorectal cancer.
The purpose of this funding opportunity is to support local interventions to address the burden of cancer in communities and across the state.
This funding will support awards, valued at $1,000 each to implement one of the six (6) community interventions listed in the attached solicitation.
Please see the attached, Solicitation for Applications, to learn about applicant eligibility, funding, project deliverables, and the application process.
Applications will be accepted starting immediately and will be reviewed and awarded in the order received on a rolling basis until funds are no longer available.
Once you’ve reviewed the attachment, please click on the link to the Community Project Application below to apply:
Community Project Application
If you have any questions, or need any assistance completing the application, please contact canserv@health.ny.gov using the subject line: Community Projects.

Application Deadline: June 15, 2021

Application

More Information

GCO Funding Opportunities

Monthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page.

STAY CONNECTED

Sign up for the Research Listserv to stay up to date with the latest news and events.